CRNX

Crinetics Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 1/10
  • Value↓ 0/10
Crinetics Pharmaceuticals sales and earnings growth
CRNX Growth
Low
  • Revenue Y/Y↑ 2277.50%
  • EPS Y/Y↓ -34.65%
  • FCF Y/Y↓ -55.64%
Crinetics Pharmaceuticals gross and profit margin trends
CRNX Profitability
Neutral
  • Gross margin ↑ 92.90%
  • EPS margin↓ -2747.20%
  • ROIC 5Y↓ -46.36%
Crinetics Pharmaceuticals net debt vs free cash flow
CRNX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Crinetics Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks